Skip to main content
  • Home
  • About
  • Faculty Experts
  • For The Media
  • ’Cuse Conversations Podcast
  • Topics
    • Alumni
    • Events
    • Faculty
    • Library
    • Research
    • Students
    • All Topics
  • Contact
  • Submit
STEM
  • All News
  • Arts & Culture
  • Business & Economy
  • Campus & Community
  • Health & Society
  • Media, Law & Policy
  • STEM
  • Veterans
  • |
  • Alumni
  • The Peel
  • Athletics
Sections
  • All News
  • Arts & Culture
  • Business & Economy
  • Campus & Community
  • Health & Society
  • Media, Law & Policy
  • STEM
  • Veterans
  • |
  • Alumni
  • The Peel
  • Athletics
  • Home
  • About
  • Faculty Experts
  • For The Media
  • ’Cuse Conversations Podcast
  • Topics
    • Alumni
    • Events
    • Faculty
    • Library
    • Research
    • Students
    • All Topics
  • Contact
  • Submit
STEM

Chemist Develops Potential Drug to Treat Type 2 Diabetes Without Harsh Side Effects

Sunday, July 12, 2020, By Dan Bernardi
Share
BioInspiredCollege of Arts and SciencesfacultyresearchSTEM
head shot

Robert P. Doyle

Robert P. Doyle, the Laura J. and L. Douglas Meredith Professor in the Department of Chemistry in the College of Arts and Sciences and adjunct associate professor of medicine at SUNY Upstate Medical University, has developed a new drug lead to treat type 2 diabetes in millions of patients who are seeking to better control their blood sugar without the common side effects of nausea, vomiting and, in select cases, undesired weight loss. His research article, “Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis,” has been published in the prestigious journal Cell Reports.

A common group of drugs used to treat type 2 diabetes are glucagon-like peptide-1 receptor (GLP-1R) agonists. While they do lower blood sugar levels in diabetic patients, their side effects include nausea, vomiting and weight loss.

Through a grant from the National Institutes of Health (NIH), Doyle and his team found a way to combine two molecules into a new substance that so far seems to lower blood sugar without those undesired side effects.

In technical terms, the team developed a new area of bioconjugation—a chemical technique used to couple two molecules. By binding together exendin-4 (Ex4), an FDA-approved GLP-1R agonist, to dicyanocobinamide (Cbi), which is a small piece of the complex vitamin B12 molecule, they produced Cbi-Ex4 in a technique they call “corrination.”

Data collected from testing Cbi-Ex4 in the musk shrew (Suncus murinus), the mammal used in this study due to its ability to vomit (rodents and many mammals lack that ability), revealed beneficial effects as evidenced by improved blood sugar levels during glucose tolerance tests and a profound reduction in vomiting compared to Ex4. Importantly, no weight loss was noted, again in stark contrast to the currently approved GLP-1R agonist, making this new drug ideal for patients who require glucoregulation without affecting their body mass index (BMI) levels. This drug could therefore benefit diabetes patients who also live with cystic fibrosis, COPD, sarcopenia, cancer or HIV, where weight-loss is counter-indicated.

The next step in the development of this groundbreaking drug is to move it through the pre-clinical phase into phase I human studies. Doyle and his team have submitted a new grant proposal to the NIH to fund this effort.

Doyle’s research was conducted in collaboration with the labs of Matt Hayes, professor in the Department of Psychiatry, University of Pennsylvania, and Bart C. De Jonghe, professor in the Department of Biobehavioral Health Sciences, University of Pennsylvania.

  • Author

Dan Bernardi

  • Recent
  • Carnegie Library Collections Move, Now Available Upon Request
    Monday, February 6, 2023, By Cristina Hatem
  • Award-Winning Comics Theorist Scott McCloud ’82 to Present Lecture Feb. 9
    Friday, February 3, 2023, By Erica Blust
  • University Monitoring Wind Chill Warning for Friday, Feb. 3
    Thursday, February 2, 2023, By News Staff
  • NASA Honoring Those Who Were Aboard Space Shuttle Columbia And Other Late Astronauts
    Thursday, February 2, 2023, By Julia Mazzer
  • NFL, Eagles and Chiefs All Set To Win The Economics Game In Super Bowl LVII
    Thursday, February 2, 2023, By Julia Mazzer

More In STEM

Donor’s ‘Belief in Potential’ Motivates $1.5M Gift

Like many young women with an interest in science, Laura Feldman ’81 thought about a career in medicine when she entered Syracuse University. But she was daunted by the statistics and her future prospects: At the time, women were not…

On Tragedy’s Anniversary, Former NASA Leader Sean O’Keefe Reflects on the ‘Price of Diligence’

The Columbia shuttle was scheduled to land at the John F. Kennedy Space Center in Cape Canaveral, Florida, on the morning of Feb. 1, 2003, after completing a successful 16-day research mission. Joining the families of the ship’s seven-member crew…

Syracuse University Environmental Finance Center Receives Multi-Million Dollar Environmental Protection Agency Grant to Support Underserved Communities

The Syracuse University Environmental Finance Center (SU-EFC) was selected by the United States Environmental Protection Agency (EPA) to serve as a regional Environmental Finance Center (EFC) to help communities access federal infrastructure funds and continue supporting environmental and financial challenges in…

Getting to the ‘Point’: Powerful Computing Helps Identify Potential New Treatments for Coronaviruses

Coronaviruses, such as the one that causes COVID-19, have numerous protruding spikes salting their surfaces. When a coronavirus raises one of these spike proteins—like opening a finger to full length—it becomes capable of invading a human cell. The pointed spike…

Researchers Reject 30-Year-Old Paradigm: Emergence of Forests Did Not Reduce CO2 in Atmosphere

It’s hard to imagine our planet without trees. From providing wildlife habitat to reducing erosion and absorbing carbon dioxide (CO2) from the air, trees play an important role in maintaining a livable environment. But trees haven’t been around forever. Over…

Subscribe to SU Today

If you need help with your subscription, contact sunews@syr.edu.

Connect With Us

  • Twitter
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
Social Media Directory

For the Media

Find an Expert Follow @SyracuseUNews
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • @SyracuseU
  • @SyracuseUNews
  • @SUCampus
  • Social Media Directory
  • Accessibility
  • Privacy
  • Campus Status
  • Syracuse.edu
© 2023 Syracuse University News. All Rights Reserved.